Headlines
Business
Politics
Technology
Sports
Markets
World
Catalyst Pharmaceutical Partners Inc. - Get News & Ratings Daily
Enter your email address below to get the latest news and analysts' ratings for Catalyst Pharmaceutical Partners Inc. with our FREE daily email newsletter:
Social Media
Follow WKRB News on Facebook Follow WKRB News on Twitter Follow WKRB News on Google Plus Subscribe to our RSS Feed
Recent Posts
Sagard Capital Partners, L.P. Sells 5,500 Shares of Hudson Global Inc (HSON) Stock
Bradley D. Goskowicz Buys 1,000 Shares of MOCON, Inc. (MOCO) Stock
Palisade Capital Management LLC NJ Purchases 47,716 Shares of Tractor Supply Company (TSCO)
Umpqua Holdings Corp to Issue Quarterly Dividend of $0.16 (UMPQ)
China Telecom Co. Limited (CHA) Cut to “Neutral” at Citigroup Inc.
Vetr Inc. Upgrades Regeneron Pharmaceuticals Inc (REGN) to Strong-Buy
Rackspace Hosting, Inc. (RAX) Rating Increased to Hold at Vetr Inc.
LinkedIn Corp (LNKD) Rating Lowered to Strong Sell at Vetr Inc.
CF Industries Holdings, Inc. (CF) Rating Increased to Buy at Vetr Inc.
PowerShares QQQ Trust, Series 1 (QQQ) Rating Increased to Hold at Vetr Inc.
Goldman Sachs Reiterates “Neutral” Rating for Provident Financial plc (PFG)
Vetr Inc. Upgrades Skyworks Solutions Inc (SWKS) to “Strong-Buy”
Vetr Inc. Upgrades Advanced Micro Devices, Inc. (AMD) to Buy
Vetr Inc. Upgrades ACADIA Pharmaceuticals Inc. (ACAD) to “Strong-Buy”
KLR Group Reiterates “Buy” Rating for Core Laboratories (CLB)
Mesirow Financial Investment Management US Value Equity Takes Position in Tristate Capital Holdings Inc (TSC)
Brookfield Renewable Energy Partners LP (BEP) Stock Rating Reaffirmed by RBC Capital
Acorda Therapeutics Inc (ACOR) Director Sells $30,223.38 in Stock
Acorda Therapeutics Inc (ACOR) Director Sells $30,223.38 in Stock
Boston Private Financial Hldg Inc (BPFH) Stock Rating Upgraded by Zacks Investment Research
Catalyst Pharmaceutical Partners, Inc. (CPRX) Given Buy Rating at HC Wainwright
Posted by Kristian Gore on Jun 15th, 2016 // No Comments
Catalyst Pharmaceutical Partners, Inc. logoHC Wainwright reissued their buy rating on shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) in a research note released on Tuesday.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) opened at 0.70 on Tuesday. Catalyst Pharmaceutical Partners has a one year low of $0.51 and a one year high of $5.80. The company’s 50-day moving average price is $0.63 and its 200-day moving average price is $1.43. The stock’s market cap is $58.01 million.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.07) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). Analysts forecast that Catalyst Pharmaceutical Partners will post ($0.28) EPS for the current fiscal year.
Several other research analysts have also recently commented on CPRX. Piper Jaffray reissued a buy rating and set a $6.00 target price (down from $10.00) on shares of Catalyst Pharmaceutical Partners in a research note on Wednesday, February 17th. Zacks Investment Research cut Catalyst Pharmaceutical Partners from a hold rating to a sell rating in a research note on Friday, February 19th. SunTrust reissued a buy rating and set a $6.00 price objective (down from $7.00) on shares of Catalyst Pharmaceutical Partners in a research report on Saturday, February 20th. Finally, Roth Capital restated a buy rating and set a $3.25 target price (down from $7.00) on shares of Catalyst Pharmaceutical Partners in a research note on Tuesday, February 23rd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $5.00.
In related news, CEO Patrick J. Mcenany bought 105,300 shares of the stock in a transaction dated Tuesday, June 14th. The stock was acquired at an average price of $0.65 per share, for a total transaction of $68,445.00. Following the acquisition, the chief executive officer now owns 4,393,109 shares in the company, valued at approximately $2,855,520.85. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Patrick J. Mcenany bought 50,000 shares of the stock in a transaction dated Tuesday, April 26th. The stock was bought at an average price of $0.65 per share, with a total value of $32,500.00. Following the acquisition, the chief executive officer now owns 4,287,809 shares in the company, valued at approximately $2,787,075.85. The disclosure for this purchase can be found here.
A number of large investors recently made changes to their positions in CPRX. Goldman Sachs Group Inc. raised its stake in shares of Catalyst Pharmaceutical Partners by 265.1% in the first quarter. Goldman Sachs Group Inc. now owns 101,855 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 73,958 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Catalyst Pharmaceutical Partners during the first quarter valued at about $206,000. A.R.T. Advisors LLC raised its position in shares of Catalyst Pharmaceutical Partners by 568.7% in the first quarter. A.R.T. Advisors LLC now owns 225,528 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 191,800 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Catalyst Pharmaceutical Partners by 20.0% in the first quarter. TIAA CREF Investment Management LLC now owns 308,113 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 51,252 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Catalyst Pharmaceutical Partners by 0.9% in the first quarter. Geode Capital Management LLC now owns 479,987 shares of the biopharmaceutical company’s stock valued at $561,000 after buying an additional 4,314 shares during the last quarter.
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceutical Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
« Previous
Infinity Pharmaceuticals Inc. (INFI) Downgraded by JMP Securities to “Market Perform” Next »
NetSuite Inc (N) Receives New Coverage from Analysts at BMO Capital Markets
Latest News
Teva Pharmaceuticals Suspends Sales of Sumatriptan Patch
Teva Pharmaceuticals Suspends Sales of Sumatriptan Patch Shooter at Gay Nightclub in Florida Is Dead Say Authorities
Shooter at Gay Nightclub in Florida Is Dead Say Authorities CEO of Airbnb Brain Chesky Has Vowed to Overhaul Site
CEO of Airbnb Brain Chesky Has Vowed to Overhaul Site Tourists Afraid to Visit Turkey, Egypt and Tunisia
Tourists Afraid to Visit Turkey, Egypt and Tunisia The Greatest is Dead, Muhammad Ali Dies at 74
The Greatest is Dead, Muhammad Ali Dies at 74 How Americans and Others Are Buying Less Expensive Drugs
How Americans and Others Are Buying Less Expensive Drugs
Leave a Reply
Name (Required)
Mail (will not be published) (Required)
Website
Around the Web
Ads by Adblade
Show your love for the USA while staying prepared. This FREE Paracord has hundreds of survival uses!
Survival Frog
5 Amazing Retirement Tips Everyone Should Know
Matson Money
These 33 Rarely Seen Photos From History Are Pretty Unnerving
World Lifestyle
Florida Homeowners Who Have Not Missed A Payment in 3 Years Are In For A Big Surprise...
Comparisons
Learn how to discretely monitor your kids online activity, including deleted text messages
Web Watcher
